Friday, July 10, 2026

pharma · Glycogen storage disease type II · Niemann-Pick disease

Sanofi Winthrop Industrie

CE SANOFI WINTHROP is a pharma organization headquartered in ANTONY, FR. Primary therapeutic focus areas include Glycogen storage disease type II, Niemann-Pick disease. NovaPharmaNews links 2 clinical program(s), 0 drug

ANTONY, FR HQ
12 Employees
EMA registrant Type
Company details
Status
Public
HQ
ANTONY, FR
Employees
12
Programs
2
Drugs
6
Patents
0
Clinical program

PTA17333

Approved · small molecule · Glycogen storage disease type II

PTA17333 for Glycogen storage disease type II is a Approved program (small_molecule) at Sanofi Winthrop Industrie with 1 ClinicalTrials.gov record(s).

← All Sanofi Winthrop Industrie projects Approved small molecule active

Internal code PTA17333

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Sanofi Winthrop Industrie
Phase
Approved
Modality
small_molecule
Indication
Glycogen storage disease type II
Status
active
Trials
1